|
|||||
|
|
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder |
|
| Authors: | William A. Ball Duane B. Snavely Richard J. Hargreaves Armin Szegedi Christopher Lines Scott A. Reines |
| Affiliation: | Merck & Co., Inc., Whitehouse Station, New Jersey, USA |
| Abstract: | |
| Keywords: | aprepitant paroxetine NK1 SSRI major depressive disorder combination treatment |